…
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
XTL Biopharmaceuticals Ltd ADR is a small, publicly listed biopharmaceutical company; publicly available information about its pipeline and commercial products is limited. Its long-term growth may depend on progression of therapeutic candidates through clinical development, successful licensing or partnerships, and regulatory approvals that could support commercialization, and investors may find exposure to potential upside from clinical-stage therapeutics attractive if development milestones are achieved.
The main risks include early-stage development and clinical and regulatory failure, limited public disclosure and liquidity, and the need for additional financing that could dilute shareholders.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -1.35M | 0.43M | -0.78M | -1.35M | 2.99M |
| Net income | -2.31M | 1.90M | -0.62M | -1.28M | 2.99M |
| Selling general administrative | 0.85M | 1.00M | 0.91M | 0.81M | 0.76M |
| Gross profit | -0.46M | 1.47M | 0.03M | 0.07M | 0.05M |
| Reconciled depreciation | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Ebit | -0.88M | -1.03M | -0.95M | -0.84M | -8.35M |
| Ebitda | -0.39M | -2.50M | -1.08M | -0.27M | -4.49M |
| Depreciation and amortization | 0.49M | -1.47M | -0.14M | 0.57M | 3.86M |
| Operating income | -0.88M | -1.03M | -0.95M | -0.84M | -0.79M |
| Other operating expenses | 0.88M | 1.03M | 0.95M | 0.84M | 0.79M |
| Interest expense | 0.47M | 1.47M | 0.03M | 0.03M | 0.08M |
| Interest income | 0.04M | 0.01M | 0.03M | 0.09M | 0.09M |
| Net interest income | 0.03M | 0.00M | 0.02M | 0.06M | 0.08M |
| Income tax expense | 0.96M | -1.47M | -0.17M | -0.07M | -7.64M |
| Total revenue | -0.46M | 1.47M | 0.03M | 0.07M | 0.05M |
| Total operating expenses | 0.88M | 1.03M | 0.95M | 0.84M | 0.79M |
| Cost of revenue | - | - | - | - | 0.00M |
| Total other income expense net | -0.47M | 1.47M | 0.17M | -0.51M | 3.70M |
| Net income from continuing ops | -1.35M | 0.43M | -0.78M | -1.35M | 2.99M |
| Net income applicable to common shares | -1.35M | 0.43M | -2.95M | -1.35M | 2.99M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 2.43M | 4.19M | 6.62M | 6.50M | 7.21M |
| Intangible assets | 0.38M | 0.38M | 0.38M | 0.38M | 0.38M |
| Other current assets | 0.01M | 0.01M | 0.02M | 0.01M | 0.10M |
| Total liab | 0.21M | 0.19M | 1.28M | 0.25M | 0.23M |
| Total stockholder equity | 2.22M | 4.00M | 5.33M | 6.25M | 6.98M |
| Other current liab | 0.20M | 0.18M | 0.23M | 0.25M | 0.23M |
| Common stock | 14.12M | 14.12M | 14.12M | 13.18M | 13.18M |
| Capital stock | 14.12M | 14.12M | 14.12M | 13.18M | 13.18M |
| Retained earnings | -158.25M | -156.47M | -155.13M | -154.66M | -153.93M |
| Other liab | - | - | 1.05M | 2.64M | 0.47M |
| Cash | 1.40M | 2.09M | 2.97M | 3.63M | 4.46M |
| Total current liabilities | 0.21M | 0.19M | 0.23M | 0.25M | 0.23M |
| Net debt | -1.40M | -2.09M | -2.97M | -3.63M | -4.46M |
| Other stockholder equity | 0.15M | 146.33M | 146.33M | 147.71M | 147.71M |
| Property plant equipment | - | - | 0.00M | 0.00M | 0.00M |
| Total current assets | 2.05M | 3.81M | 6.24M | 6.12M | 6.83M |
| Net tangible assets | - | 3.62M | 4.95M | 3.23M | 6.60M |
| Short term investments | 0.60M | 1.63M | 3.16M | 2.41M | 2.27M |
| Net receivables | 0.03M | - | - | - | - |
| Accounts payable | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Accumulated other comprehensive income | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M |
| Common stock total equity | - | - | - | 13.18M | 13.18M |
| Non currrent assets other | 0.60M | - | - | - | 0.00M |
| Non current assets total | 0.38M | 0.38M | 0.38M | 0.38M | 0.38M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | 0.04M | 0.04M | 0.01M | 0.03M | 2.11M |
| Change to liabilities | - | 0.00M | -0.02M | 0.02M | -0.02M |
| Total cashflows from investing activities | - | 0.04M | 0.01M | 0.03M | 2.11M |
| Total cash from financing activities | 0.00M | 0.00M | 0.39M | 0.39M | 0.39M |
| Change to operating activities | - | - | -0.03M | 0.02M | -0.03M |
| Net income | -1.78M | -1.35M | 0.43M | -0.78M | -1.35M |
| Change in cash | -0.69M | -0.88M | -0.66M | -0.82M | 1.20M |
| Begin period cash flow | 2.09M | 2.97M | 3.63M | 4.46M | 3.25M |
| End period cash flow | 1.40M | 2.09M | 2.97M | 3.63M | 4.46M |
| Total cash from operating activities | -0.71M | -0.90M | -1.05M | -0.85M | -0.91M |
| Issuance of capital stock | - | - | - | - | 0.00M |
| Depreciation | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Other cashflows from investing activities | - | 0.04M | 0.01M | 0.03M | 0.09M |
| Other cashflows from financing activities | 0.04M | 0.04M | 0.39M | 0.03M | 2.11M |
| Change to netincome | - | 0.45M | -1.43M | -0.11M | 0.49M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.06M | -0.02M | -0.05M | 0.04M | -0.05M |
| Stock based compensation | 0.00M | 0.01M | 0.04M | 0.05M | 0.01M |
| Other non cash items | -0.04M | 0.45M | -0.01M | -0.03M | 0.48M |
| Free cash flow | -0.71M | -0.90M | -1.05M | -0.85M | -0.91M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| XTLB XTL Biopharmaceuticals Ltd ADR |
-0.08 4.94% |
1.54 | - | - | - | 5.67 | -6.58 |
| NVO Novo Nordisk A/S |
-1.25 3.07% |
39.45 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
- -% |
536.45 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-9.75 1.02% |
948.01 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
| Name | Title | Year Born |
|---|---|---|
| Mr. Shlomo Spokone Shalev | CEO & Director | 1962 |
| Mr. Itay Weinstein | Chief Financial Officer | 1971 |
| Mr. Ronen Kantor | Company Sec. | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.